Press Releases

GlobeNewswire, Inc.

Data from the RALLY-MF trial of DISC-0974 in patients with myelofibrosis (MF) and anemia demonstrate meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status or concomitant JAK inhibitor...

EIN Presswire

Session Explores How HealthTech Organizations Can Build Authority and Earn Citations in AI-Generated Search Results GOTHENBURG, GOTHENBURG, SWEDEN, June 12, 2026 /⁨EINPresswire.com⁩/ -- May 2026 Anastasiia Sosyniuk, co-founder of Go Global and an...

GlobeNewswire, Inc.

SAN DIEGO, June 11, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for...

GlobeNewswire, Inc.

– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups, including 70% (14/20) CR/CRh in...

GlobeNewswire, Inc.

Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the high dose cohort, with additional...

GlobeNewswire, Inc.

– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib with intensive chemotherapy in newly diagnosed NPM1m...

GlobeNewswire, Inc.

Priority review recognizes the serious nature of epidermolysis bullosa (EB) and the urgent need for continued evaluation of potential treatment options If approved, FILSUVEZ has the potential to become the first therapy approved by Health Canada...

GlobeNewswire, Inc.

More than 100 patients treated with ronde-cel in 2L and 3L+ LBCL, with a manufacturing success rate of 97% No Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS, supporting outpatient administration Translational data support biological basis for...

GlobeNewswire, Inc.

-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria – -- Bezuclastinib demonstrated a powerful effect...

EIN Presswire

Menstrual Cup Market to Surge from USD 1.04 Billion in 2026 to USD 1.62 Billion by 2035 — Powered by Sustainability & Plastic Reduction Mandates NY, CA, UNITED STATES, June 12, 2026 /⁨EINPresswire.com⁩/ -- As per Market Research Future, the global...

GlobeNewswire, Inc.

- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145, on track for IND in 2026 - WALTHAM, Mass. and...

GlobeNewswire, Inc.

PARMA, Italy, June 05, 2026 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced that the European...

MENAFN

(MENAFN) Sweden's Public Health Agency issued a stark warning to parents Monday, calling on them to significantly reduce personal mobile phone use in the presence of children — pointing to a mounting body of evidence that adults' own screen habits...

MENAFN

(MENAFN) Sweden’s Public Health Agency has issued a new recommendation urging parents to limit their mobile phone use in the presence of children, pointing to growing evidence that adult screen habits can have a negative impact on child...

GlobeNewswire, Inc.

CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its proprietary brand, Sky Premium Life, is now...

GlobeNewswire, Inc.

-- At ERA 2026, Chiesi will contribute to advancing the scientific understanding of Fabry disease and nephropathic cystinosis through real-world experience and clinical outcomes, supporting the needs of the community of today -- -- Chiesi will...

GlobeNewswire, Inc.

BEDFORD, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver...

GlobeNewswire, Inc.

Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals Appointment strengthens confidence in clinical readiness and execution as the Company progresses toward...

GlobeNewswire, Inc.

In a post hoc analysis, patients treated with roxadustat showed a durable and clinically meaningful improvement in transfusion independence (TI) in patients with LR-MDS and high transfusion burden (HTB) compared to placebo Similar rates of TI for...

GlobeNewswire, Inc.

SEATTLE, May 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat...